← Leaderboards
Dylan A. McCreedy
University Of California, San Francisco
$2,138,668
Attributed
$2,138,668
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $463.9K · FY2016–25$500K$375K$250K$125K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,138,668 · 2
By mechanism
R01$1,964,636 · 1
F32$174,032 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Andrea K Garber$3,633,516
- Donna M. Ferriero$20,040,301
- Neville Hylton Golden$2,174,922
- Tingting Hong$5,335,730
- Samuel I Mann$864,284
Others in their field
Top investigators on “Spinal Cord”
- William G Barsan · University Of Michigan At Ann Arbor$41,978,947
- Martyn D Goulding · Salk Institute For Biological Studies$29,923,021
- P. Hunter Peckham · Case Western Reserve University$26,617,663
- Aron S Buchman · Rush University Medical Center$24,245,202
- Mark H Tuszynski · University Of California, San Diego$22,931,521
- Gordon Stewart Mitchell · University Of Florida$21,771,368
Research focus
Spinal CordRecoveryKnock-In MouseRehabilitation TherapyPlayReceptorHourInjuryNeutrophilNeurological RecoveryFda ApprovedAdhesion ReceptorBehaviorReactive Oxygen SpeciesBloodAdhesionsInflammationInflammatoryEventDiclofenacEffective TherapyL-SelectinAttenuatedSpinal Cord Injury
Grant awards (11)
L-selectin shedding as a novel therapeutic strategy to mitigate acute secondary damage after spinal cord injury$364,688
R01 · FY2025 · NS · contact PI
L-selectin shedding as a novel therapeutic strategy to mitigate acute secondary damage after spinal cord injury$354,397
R01 · FY2024 · NS · contact PI
L-selectin shedding as a novel therapeutic strategy to mitigate acute secondary damage after spinal cord injury$46,078
R01 · FY2024 · NS · contact PI
L-selectin shedding as a novel therapeutic strategy to mitigate acute secondary damage after spinal cord injury$365,995
R01 · FY2023 · NS · contact PI
L-selectin shedding as a novel therapeutic strategy to mitigate acute secondary damage after spinal cord injury$72,024
R01 · FY2023 · NS · contact PI
Supplement: L-selectin shedding as a novel therapeutic strategy to mitigate acute secondary damage after spinal cord injury$25,846
R01 · FY2023 · NS · contact PI
L-selectin shedding as a novel therapeutic strategy to mitigate acute secondary damage after spinal cord injury$367,537
R01 · FY2022 · NS · contact PI
L-selectin shedding as a novel therapeutic strategy to mitigate acute secondary damage after spinal cord injury$368,071
R01 · FY2021 · NS · contact PI
The role of L-selectin in leukocyte recruitment and longer term recovery after spinal cord injury$55,040
F32 · FY2018 · NS · contact PI
The role of L-selectin in leukocyte recruitment and longer term recovery after spinal cord injury$60,990
F32 · FY2017 · NS · contact PI
The role of L-selectin in leukocyte recruitment and longer term recovery after spinal cord injury$58,002
F32 · FY2016 · NS · contact PI